- Home
- ADIL vs CNSP Comparison
ADIL vs CNSP Comparison
Compare ADIL & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADIL | CNSP |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3M | 7.5M |
| IPO Year | 2017 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ADIL | CNSP |
|---|---|---|
| Price | $4.99 | $5.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $37.50 | $20.00 |
| AVG Volume (30 Days) | ★ 61.8K | 5.7K |
| Earning Date | 05-13-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.03 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.13 | $1.90 |
| 52 Week High | $5.17 | $10.59 |
Technical Indicators
Market Signals| Indicator | ADIL | CNSP |
|---|---|---|
| Relative Strength Index (RSI) | 65.51 | 54.59 |
| Support Level | $2.38 | $4.58 |
| Resistance Level | $5.08 | $5.72 |
| Average True Range (ATR) | 0.50 | 0.32 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 75.79 | 72.27 |
Price Performance
Historical ComparisonAbout ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. The company operates as one operating segment with a focus on drug development for addiction and related disorders.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.